In our previous study, a relationship between low expression of D2-like dopamine receptor genes and non-small cell lung cancer (NSCLC) disease was found. In this new research, by using selective agonist of these receptors, Dromocriptine (DR), we attempted to activate D2-like expression and apoptotic induction in a selective cell line of NSCLC. In addition, the relationship of apoptotic response of human lung carcinoma cells to DR and D2-dopamine receptor genes is investigated. Human lung cancer (QU-DD) cells were treated by five doses of DR at 48 h and cell viability was determined by MTT assay. The gene expression pattern of D2-like dopamine receptor Genes was studied by Real Time PCR. Nuclear morphology of cells was monitored by DAPI florescent staining then induction of DNA fragmentation by DR was shown in an agarose gel. Finally, the detection and quantification of apoptosis and its differentiation from necrosis was carried out by using Annecxin-V-Fluos Staining. In this study, it is demonstrated that DR inhibited the proliferation of human lung cancer cells and induced apoptosis in them. In addition, the probable relationship between D2-dopamine receptor genes expression and the development of apoptosis was found. In conclusion, DR is responsible for induction of apoptosis in human lung cancer cells and can be used in treatment of these tumoric cells. In addition, normal expression of D2 dopamine receptors was associated with apoptotic effect of DR on these cells.
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Lung cancer is the most common cancer in the world (1) (2) . Despite several advances in surgery, chemotherapy, and radiotherapy over the past decades, the mortality rate of lung cancer has remained largely unchanged, which is mainly due to metastatic disease (3) . Because of the overall poor prognosis, new treatment strategies for lung cancer patients are urgently needed. Recent studies have provided new evidence that Dopamine has an important role in the renal, hormonal and central nervous systems. The dopaminergic pathway may be of interest in assessing risk oflung cancer (4) (5) . Dopamine receptor D2 exists extensively in different pulmonary carcinoma cells. The presence ofD2 dopamine-like receptors in small cell lung cancer cell line (NCI-H69) was previously established by the use of iodosulpride binding and has been confirmed using reverse transcription PCR with receptor-specific primers (6) .
The dopaminergic pathway may be of interest in assessing risk of non-small cell lung cancer (NSCLC). Dopamine receptors are expressed in alveolar epithelial cells and human lung tumors. Dopamine inhibits both cell proliferation in vitro and growth of lung tumor xenografts in nude mice. Moreover, dopamine selectively inhibits the vascular permeability and angiogenic activity of vascular endothelial growth factor (VPFNEGF) (7) (8) (9) . Dopamine and its agonists may promote the apoptosis of carcinoma cells through dopamine receptor 02 (10) . Bromocriptine (BR), dopamine agonist, is an accepted primary therapeutic agent for adenomas. BR binds to the dopamine 02 receptors on pituitary epithelial cells to inhibit prolactine (PRL) secretion. BR, is now indicated for use in treatment of Parkinson's disease, acromegaly, cocaine addiction, hyperprolactinemia-associated dysfunctions, neuroleptic malignant syndrome, cyclical mastalgia and type 2 diabetes (11) (12) . The chemical hypothesis behind all of these conditions is a reduction in the secretion of the neurotransmitter dopamine in specific parts of the brain. BR acts as a substitute for dopamine and stimulates dopamine receptors (10) . BR is an accepted therapeutic agent for patients with prolactinomas, growth hormone-secreting and elevated serum level of prolactin or growth hormone and shrinks such tumors by diminishing tumor cell size (13) . BR inhibits hormone and DNA biosynthesis and has anti-mitotic effects. BR binds to the dopamine 02 receptors on pituitary epithelial cells to inhibit prolactine (PRL) secretion (14) . 02 receptor mRNA was found in all BR-sensitive tumors but was not detected in BR-resistant tumors, indicating a full concordance between tumoric responses to BR and the expression of 02 receptor (15) . As in the previous study conducted by the authors, it WAS observed thaT significant changes can occur in D2-like dopamine gene receptor expression associated with NSCLC (16) . In this paper, apoptosis was investigated in a lung carcinoma cell line as an in vitro model of NSCLC using selective agonist of these receptors (BR).
MATERIALS AND METHODS
BR mesylate was obtained from BIOTREND chemical AG (Zurich, Switzerland) in powder form, where a 25 mM stock solution was prepared in methanol. Human lung carcinoma cell line (QU_DB) was provided from the National Cell Bank of Iran (NCBI) (Pasteur Institute, Iran). Human lung cell line (HFLF-PI5) that was derived from the lung tissue of a 14-week-old fetus in NCBI was used in the whole process of the study as a control.
Cell Culture was carried out with QU-DB cells in DMEM and HFIF cells in RPMI 1640 medium were grown, supplemented with 10% fetal bovine serum, in a humidified atmosphere of 5% CO 2 and 95% air at 37°C.
Cell viability test was then carried out. The effects of BR on cell proliferation were investigated by MTT assay (17) . Cells were seeded at 10 4 cells/well (0.1 ml) in triplicate in a 96-well plate and treated with varying doses of BR (0. 6.25, 12.5, 25, 37.5and 50llmol/L) following a 48-h period of incubation at 37°C, 10 III of MTT reagent(3-4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasolium bromide) was added to each well. Following another 4-h period of incubation at 37°C, the supernatant was removed from each well. The colored formazan crystals which were produced from MTT were dissolved in OMSO (sigms. USA) and absorbance was then measured at 570 nm by an ELISA plate reader (ELX800™, USA).
Dopamine receptors gene expression study was carried out. The analysis of D2-like dopamine receptors (02, 03, and 04) expression was performed before and after BR treatment. RNA was extracted from samples using the RNA Blood minikit (Roche, Germany). The amount and purity of RNA was determined by a spectrophotometer and agarose gel electrophoresis (18) (19) (20) . Dopamine receptor mRNA expression was determined by the fluorogenic cyber green approach (Roche, Germany). Total RNA was transcribed into first strand cDNA using oligonucleotide dT primers and 2.5 Units of multiscribe (recombinant Maloney murine leukemia virus) reverse transcriptase. Samples of cDNA were used for PCR amplification in a final volume of 25 III with 1 Unit oftaq DNA polymerase (Roche, Germany). Real -Time PCR (RT-PCR) was carried out using primer pairs specific for D2-like dopamine receptors mRNA and -actin (as internal control) (Table I ) with a cyber green flurogenic nucleotide to monitor cDNA amplification via an increase in fluorescence intensity(Corbett, Germany). These experiments were repeated thrice for each receptor. Finally, statistical analyses were performed with the software package, linreg &REST.
Analysis of DNA Fragmentation was made by Agarose Gel Electrophoresis test. DNA was extracted from QU-DB cells that had been treated 48 h, using salting out method, and then DNA samples were analyzed on 2% agarose gel containing O.5llglml ethidium bromide and were visualized using 312 nm uv.
DAPI Staining methods using the blue-fluorescent DAPI is a popular nuclear counter stain for use in multicolor fluorescent techniques. Moreover, it was used for the morphological detection of apoptotic cells. BR-induced apoptosis of QU-DB cells was accomplished according to protocol as described below. Growth medium was aspirated from wells. The cells were fixed by addition of3% paraformaldehyde (PFA) solution (in PBS at pH 7.4) for 10 min incubation at Room Temperature (RT) (enough to cover the bottom of the well). Then, PFA solution was aspirated and subsequently PBS was added to the top of wells and incubated for 2 min at RT. Permeabilizing was done with 0.2% triton X-toO in PBS for 2 min incubation at RT. Triton X-I00 was aspirated and PBS was added to the top of wells and incubated 2 min at RT. Staining with DAPI was performed by aspiration of PBS, addition of DAPI and incubation in dark for 5 min at RT[stock=sigma D9542 at Img/ml, dilute I: 1000 in PBS before use]. Then washing was carried out 3 times with PBS and cells were incubated for 2 min at RT each time. Finally, stained cells were observed with fluorescent microscope (Zeiss, Germany) and a minimum of 200 cells were counted to quantify the following groups by the following method: Live cells with blue normal nuclei, apoptotic cells with blue chromatin that was highly condensed or fragmented and necrotic cells with organized chromatin structure.
% apoptoticcells_ (total no.0( cells counte<l)-(total no or live cells) x 100 total no.0( cellscounted The next test was Flow Cytometry assay. In the early stages of apoptosis, changes occur at the cell surface (21) . One of these plasma membrane alterations is the translocation of phosphatidylserine (PS) from the inner part of the plasma membrane to the outer layer, in which PS becomes exposed at the external surface of the cell (22). Fadok et al. showed that macrophages specifically recognize PS exposed on the surface of lymphocytes during the development of apoptosis. The recognition and phagocytosis of apoptotic cells and bodies protects organisms from the exposure to cellular compounds leading to inflammation, which mostly accompanies necrosis. The analysis of phosphatidylserine on the outer leaflet of apoptotic cell-membranes is performed using Annexin-V-Fluorescein and proidium iodide (PI) for the differentiation from necrotic cells or labeling with a cell surface marker for cell characterization. QU-DB cells were treated with different concentration of BR (0, 6.25, 12.5, 25, 37.5 and 50 umol/L) for 48 h (treatments were repeated thrice for each concentration). It should be noted that Annexin-V-Fluos staining kit (roche, Germany) is used for the detection and quantification of apoptosis and differentiation from necrosis at single cell level. For preparation of Annexin-V-FLUOS labeling solution 20 III Annexin-V-Fluos labeling reagent was prediluted in I ml incubation buffer and 20 III propidium iodide solution was added, then the cell pellet which was treated by BR was resuspended in 100 III ofAnnexin-V-Fluos solution, incubated 15 min at 25°C and analyzed on a flowcytometer (BD,USA) by a Flowmax software.
The statistical analyses for D2-like dopamine receptor gene expression were performed with the software package, linreg &REST. Statistical significance was defined as p<0.05.
RESULTS
QU-DB cells were treated in triplicate with different concentration ofBR (0, 6.25, 12.5,25,37.5 and 50 umol/L) to determine the effect ofthis drug on cell proliferation and an MTT assay was performed after treatment. As shown in Fig. I , BR inhibited growth of these cancer cells in a dose-dependent manner and significant changes were observed at concentrations ranging between 12.5 to 251lmollL.
To determine whether BR has an effect on the expression levels of D2-like dopamine receptors, QU-DB cells before and after treatment with different doses of BR were analyzed by total RNA extraction from treated cells, eDNA synthesis and Real Time PCR reaction test of D2, D3 and D4 dopamine receptor genes (Corbett, Germany). Then statistical analysis was carried out using linreg software and Rest analysis method. As shown in Fig. 2 , increased expression of D2, D3 and D4 dopamine receptors significantly appeared after the treatment ofQU-DB cells by BR in two steps:
Step I at concentration of 6.251lmo1lL that is initiation process of apoptosis occurrence and step 2 at concentration of37.5Ilmol/L that increases the ratio of necrotic cells.
Intemucleosomal DNA cleavage is a characteristic biochemical hallmark of the apoptotic mode of cell death (14) . Thus, to determine whether BR induces apoptosis in QU-DB cells, the extracted DNA was examined on the agarose gel, as shown in Fig. 3 . Our findings show that DNA fragmentation was clearly induced in QU-DB cells after treatment and under the same conditions. It is worthy ofnote that no DNA fragmentation was found in untreated (control) cells.
4, 6-diamidino-2-phenylindole (DAPI) is a type of specific dye binding DNA. Once it pemnetrates cell membranes ofnormal cells, the blue fluorescence can be observed by fluorescent microscopy. With the process of apoptosis, the permeability of dye is improved and the apoptotic cells will produce high blue fluorescence. Simultaneously, for normal cells, round nucleus is stained uniformly and its margin is clear. However, for apoptotic cells, the margin of 
50
Bromocripin Cone. (micM)
Fig. 1. The effect ofvarious doses ofbromocriptine on QU-DB cells. Bromocriptine inhibited the proliferation ofQU-DB in a dose-dependent fashion .
Exp resxio n c h a n ge orDRD6 Y-GAGACC'ITCAACAca:cAGCC -3' 399 nucleus is abnormal and the condensed or fragmented chromosome is easily stained (www.genscript.com).
Therefore, in order to analyze whether QU-DB cells treated with BR displayed apoptotic morphology, cells were stained with DAPI as previously described. As shown in Fig. 4 , the maximum increase in the number ofapoptotic cells (about 45%) was observed in 12.5 umol/L ofBR. The figure magnification ofA andCis20X 10 and for B40X 10.
Flow cytometric analysis clearly differentiates normal (living cells) with low annexin and low PI staining, apoptotic cells with high annexin and low PI staining, and necrotic cells with high annexin and high PI staining. As represented in Fig. 5, a and b , maximum increase in the number of apoptotic cells (48.88%) was observed in concentration of 12.5 umol/L and the ratio of necrotic to apoptotic cells was increased at concentration of 50 umol/L and above that concentration BR had not any effect on the these carcinoma cells (Table II) .
DISCUSSION
Many studies which used dopamine ligands in therapeutics are mostly targeting the D2-family, but to date the alteration in expression of dopamine receptors in cancer disease has not been explored sufficiently. In this research, the expression of 02-like dopamine receptors in lung carcinoma cell line before and after BR treatment has been extensively studied. Moreover, it has been considered how expression ofthese receptors could relate to apoptosis. In the present study, it has been clearly revealed that BR induced apoptosis in lung carcinoma (QU-DB) cells, with concomitant activation of 02 dopamine receptors. There have been many reports of BR efficacy in these methods of therapy (23) (24) . The findings in this study demonstrate that BR clearly inhibited the rapid proliferation of lung cancer ceIls in vitro, and this significant decrease in QU-DB viability is dependent on augmentation of 02-dopamine receptor gene expression induced by BR, their selective agonist. It indicated that BR activated D2-dopamine receptors on cell membranes, and increased expression of these receptors were associated with BR-induced apoptosis in human lung carcinoma cells (25).
Previous study showed that BR activated wild-type p53 and suppressed bcl-2, favoring the occurrence of apoptosis in pituitary adenoma ceIls. Multiple signal transduction mechanisms are activated by 02 receptors in the pituitary gland. In addition to the inhibition of adenylate cyclase, 02 receptors, via G protein-dependent mechanisms, inhibit phosphatidylinositol metabolism, activate voltage-activated potassium and decrease voltageactivated L-and T-type calcium currents. D2-like receptors (02, 03, and 04) decrease intracellular cAMP accumulation through GilGo proteins and finally have an anti-mitotic effect on cell cycle (26) .
With similar results presented in this paper, researchers observed apoptotic and necrotic changes in CH3 cells (lymphatic endothelial cell line from a recurrent retroperitoneal lymphangioma) after 48-h incubation with BR at the concentrations of 25Jlmol/L (27). Comparable with these, in this research, that significant apoptotic changes (48.88%) in QU-DB cells were observed after 48-h incubation with BR at the concentration of (l2.5JlmoI/L). Miyuki Ishibashi et aI. and others have previously shown that BR inhibited the growth of human small cell lung cancer (SCLC) implanted as tumor xenografts, without any toxic side effect, in athymic nude mice and co-incubation with dopamine 02 receptor antagonist, metoclopramid, or domperidone blocked the inhibitory effect of BR. In this study, using D2-like dopamine receptor Gene expression analysis, it was demonstrated that inhibitory action of BR on human lung carcinoma cell growth is occasioned by dopaminergic stimulation. Therefore, this dopaminergic agonist is useful in the medical treatment of human lung cancer. A large body of evidence indicates that the production of autocrine growth factors by cancer cells may play an important role in the abnormal growth regulation characteristic of malignant cells (28-29). Dopamine 02 receptor activation may have suppressed the production and secretion of these autocrine growth factors with a resultant inhibition of cell growth. An explanation for growth inhibitory effect of BR in QU-DB cells may be the 02 receptor stimulation and suppression of early signal generation in the mitogenic response of these cells (30) . In this research, based on our previous dopamine receptor genes expression case control study, a relationship between low expression of D2-like dopamine receptor genes and NSCLC disease was found. Moreover, using selective agonist of these receptors, it was tempted to activate D2-like expression and apoptotic induction in a selective cell line of NSCLC in a step-by-step examination. As shown in Fig. I , BR decreased viability of QU-DB cells in a dose-dependent fashion significantly at concentrations ranging between 12.5 t025 umol/L. The extracted DNA from BR-treated cells clearly showed nucleosomal fragmentation, indicative of apoptosis. In addition, results of DAPI staining of QU-DB cells treated by BR, displayed typical apoptotic morphologies such as fragmented nuclei as shown in Fig. 4 . Finally, in the last step of this research, by flow cytometric analysis, the treated cells were clearly differentiated to apoptotic and necrotic form of human lung carcinoma cells and confirmed all of the previous results.
In conclusion, it has been suggested that dopaminergic agonists such as BR are useful in the medical management of lung cancer and the dose of BR that was used is an effective therapeutic dose in human. Since BR has FDA approval as a therapeutic drug, further experiments on NSCLC patients may lead to new approaches to the treatment of human NSCLC.
